Literature DB >> 18536860

Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD.

Gunnar Johansson1, Anne Lindberg, Kerstin Romberg, Lars Nordström, Fronke Gerken, Annika Roquet.   

Abstract

AIMS: Evaluation of tiotropium efficacy in patients with mild chronic obstructive pulmonary disease (COPD) defined by the 2003 Swedish Society of Respiratory Medicine guidelines (post-bronchodilator FEV1/FVC <70%; FEV1 >60% predicted).
METHODS: In this 12-week, randomised, double-blind, placebo-controlled study of tiotropium 18 mcg once daily versus placebo, respiratory function was assessed on Days 1, 15 and 85 (baseline: pre-dose Day 1).
RESULTS: Mean+/-SD baseline FEV1 (% predicted) was 73.4+/-12.5 (tiotropium, n=107; placebo, n=117). Tiotropium significantly improved change from baseline in area under the curve from pre-dose to 2 hours post-dose (AUC0-2 h) FEV1 versus placebo, by 166+/-26 mL (mean+/-SE) at study end (p<0.0001). With tiotropium, there were significant increases in the change in AUC0-2 h FVC versus baseline, and trough FEV1 and FVC, versus placebo, on all test days (p<0.01). Adverse event rates were similar.
CONCLUSION: Compared with placebo, tiotropium improved lung function in patients with mild COPD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18536860      PMCID: PMC6619888          DOI: 10.3132/pcrj.2008.00037

Source DB:  PubMed          Journal:  Prim Care Respir J        ISSN: 1471-4418


  22 in total

Review 1.  Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

2.  Determinants of spirometry use and accuracy of COPD diagnosis in primary care.

Authors:  Min J Joo; David H Au; Marian L Fitzgibbon; Joanne McKell; Todd A Lee
Journal:  J Gen Intern Med       Date:  2011-06-29       Impact factor: 5.128

3.  Tiotropium formulations and safety: a network meta-analysis.

Authors:  Mario Cazzola; Luigino Calzetta; Paola Rogliani; Maria Gabriella Matera
Journal:  Ther Adv Drug Saf       Date:  2016-09-16

Review 4.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

Review 5.  Tiotropium versus placebo for chronic obstructive pulmonary disease.

Authors:  Charlotta Karner; Jimmy Chong; Phillippa Poole
Journal:  Cochrane Database Syst Rev       Date:  2014-07-21

6.  Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium.

Authors:  Kai-Michael Beeh; Jutta Beier; James F Donohue
Journal:  Respir Res       Date:  2012-06-22

Review 7.  Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.

Authors:  Marie Westwood; Jean Bourbeau; Paul W Jones; Annamaria Cerulli; Gorana Capkun-Niggli; Gill Worthy
Journal:  Respir Res       Date:  2011-04-08

8.  Assessing the Impact of Tiotropium on Lung Function and Physical Activity in GOLD Stage II COPD Patients who are Naïve to Maintenance Respiratory Therapy: A Study Protocol.

Authors:  Thierry Troosters; Idelle Weisman; Fabienne Dobbels; Nicholas Giardino; Srinivas Rao Valluri
Journal:  Open Respir Med J       Date:  2011-03-15

9.  Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.

Authors:  Anthony D'Urzo; Gary T Ferguson; Jan A van Noord; Kazuto Hirata; Carmen Martin; Rachael Horton; Yimeng Lu; Donald Banerji; Tim Overend
Journal:  Respir Res       Date:  2011-12-07

Review 10.  Tiotropium HandiHaler in the treatment of COPD: a safety review.

Authors:  Steven Kesten; Bart Celli; Marc Decramer; Inge Leimer; Donald Tashkin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.